The Technical Analyst
Windtree Therapeutics Inc [WINT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Windtree Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
16.24% $4.94
America/New_York / 3 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2.52 mill |
| EPS: | -94.32 |
| P/E: | -0.0500 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 0.510 mill |
| Avg Daily Volume: | 0.0171 mill |
| RATING 2024-05-03 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0500 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.0500 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-2.25 (-145.45%) $-7.19 |
| Date: 2024-05-03 |
| Expected Trading Range (DAY) |
|---|
|
$ 4.27 - 5.62 ( +/- 13.66%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-09-27 | Fraser Craig | Buy | 2 500 | Common Stock |
| 2023-09-26 | Fraser Craig | Buy | 2 500 | Common Stock |
| 2023-08-24 | Mcandrew Jamie | Sell | 0 | Common Stock |
| 2023-08-24 | Mcandrew Jamie | Buy | 0 | Common Stock |
| 2023-08-24 | Mcandrew Jamie | Sell | 220 | Employee Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 36.22 |
| Last 96 transactions |
| Buy: 7 918 771 | Sell: 11 081 644 |
Forecast:
16:00 - $5.01
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $5.01
Forecast 2: 16:00 - $5.01
Forecast 3: 16:00 - $5.01
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.94 (16.24% ) |
| Volume | 0.125 mill |
| Avg. Vol. | 0.0171 mill |
| % of Avg. Vol | 729.47 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For WINT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
WINT
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
Latest Press Releases
2024-04-18 08:00:00 - Press Release
Windtree Therapeutics Announces Reverse Stock Split
Warrington, pa., april 18, 2024 (globe newswire) -- windtree therapeutics, inc. (nasdaq: wint) (“windtree” or the “company”), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today announced that the company's board of directors has approved a 1-for-18 reverse stock split of its issued and outstanding common stock, par value of $0.001 per share (the “reverse stock split”). the reverse stock split will become effective at 11:59 p.m. eastern time on april 19, 2024 and the company's common stock will open for trading on the nasdaq capital market on a split-adjusted basis under the symbol “wint” on april 22, 2024. at such time, the company's common stock will also commence trading under a new cusip number, 97382d 501.
2024-04-17 08:00:00 - Press Release
Windtree Therapeutics Reports Fourth Quarter And Year-end 2023 Financial Results And Provides Key Business Updates
Warrington, pa., april 17, 2024 (globe newswire) -- windtree therapeutics, inc. (“windtree” or “the company”) (nasdaqcm: wint), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the fourth quarter and fiscal year ended december 31, 2023 and provided key business updates.
2024-04-08 16:48:00 - Press Release
Windtree Acquires Early-stage, Novel Oncology Platform And Completes $1.5 Million Convertible Note Bridge Financing
Warrington, pa., april 08, 2024 (globe newswire) -- windtree therapeutics, inc. (“windtree” or the “company”) (nasdaqcm: wint), today announced that on april 2, 2024 the company entered into an asset purchase agreement with varian biopharmaceuticals, inc. (“varian”) to acquire certain of its assets, including a proprietary atypical protein kinase c iota inhibitor (apkci). the company also completed a $1.5 million convertible note bridge financing.
2024-02-01 08:00:00 - Press Release
Windtree Renews Agreement With Chang Gung University For Scientific Collaboration To Further Serca2a Research
Warrington, pa., feb. 01, 2024 (globe newswire) -- windtree therapeutics, inc. (“windtree” or the “company”) (nasdaqcm: wint), a biotechnology company focused on advancing late-stage interventions for critical cardiovascular disorders, today announced that it has renewed its partnership with chang gung university in taiwan to further research on serca2a, an important target for the company's cardiovascular portfolio. windtree personnel from its offices in taipei, taiwan will participate in the collaboration.
2024-01-31 08:00:00 - Press Release
Windtree Therapeutics Announces Engagement Of Strategic Advisor To Support Assessment Of Strategic Alternatives
Warrington, pa., jan. 31, 2024 (globe newswire) -- windtree therapeutics, inc. (“windtree” or the “company”) (nasdaqcm: wint), a biotechnology company focused on advancing late-stage interventions for critical cardiovascular disorders, today announced that it has engaged ladenburg thalmann & co. inc. (“ladenburg”) to evaluate strategic alternatives for the company with the goal of maximizing stockholder value.
Latest News
2024-04-22 11:06:19 - Invezz
What made Windtree Therapeutics stock tank 20% on Monday?
Windtree Therapeutics Inc (NASDAQ: WINT) is down nearly 20% on Monday even though there hasn't been any specific news that may have caused that decline. Here's what may be weighing on Windtree Therapeutics stock Investors may be continuing to respond to a few updates that $WINT has posted in recent days.
2023-11-08 08:00:00 - GlobeNewsWire
Windtree to Present at the Sidoti Micro Cap Conference on November 16th
WARRINGTON, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present a corporate update at the Sidoti Micro Cap Conference on Thursday, November 16, 2023 at 1:45pm ET. Windtree management will also be participating in virtual 1x1 meetings with investors at the event on November 15 and 16.
2023-10-12 07:30:00 - GlobeNewsWire
Windtree to Present at the ThinkEquity Conference on October 19th in New York City
WARRINGTON, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that Craig Fraser, President and Chief Executive Officer, will be presenting at the upcoming ThinkEquity Conference on Thursday, October 19, 2023 at 4:30pm ET. Windtree management will also be hosting 1x1 meetings with investors at the event.
2023-10-10 07:30:00 - GlobeNewsWire
Windtree to Participate in the Lytham Partners Fall 2023 Investor Conference on October 17th
WARRINGTON, Pa., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that Craig Fraser, President and Chief Executive Officer, will be participating in a panel discussion titled, “Cardiac Kids: Late-Stage Advancement for Cardiovascular Disorders,” at the Lytham Partners Fall 2023 Investor Conference on Tuesday, October 17, 2023 at 10:30am ET. Windtree management will also be participating in virtual 1x1 meetings with investors at the event.
2023-10-03 08:00:00 - GlobeNewsWire
Windtree to Present at the Dawson James Small Cap Growth Conference on October 12th
WARRINGTON, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that Craig Fraser, President and Chief Executive Officer, will be presenting at the upcoming Dawson James Small Cap Growth Conference on October 12, 2023 in Jupiter, FL.
2023-08-25 07:20:36 - InvestorPlace
7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole
Investing in biotech stocks can be challenging. The rewards can be great when your company hits on a popular drug, treatment or product.
2023-06-05 16:35:14 - PennyStocks
3 Penny Stocks To Watch Before Next Week; Time To Buy?
Penny stocks often represent an intriguing opportunity for investors. Defined by the U.S. Securities and Exchange Commission as shares trading for less than $5, these stocks generally belong to small companies that may not yet have made their mark in the mainstream market.
2023-04-20 09:24:14 - InvestorPlace
Why Is Windtree Therapeutics (WINT) Stock Down 58% Today?
Windtree Therapeutics (NASDAQ: WINT ) stock is falling on Thursday after the company announced the departure of its Chairman of the Board of Directors. James Huang is departing from Windtree Therapeutics for a couple of reasons.
2023-04-17 13:20:53 - InvestorPlace
Why Is Windtree Therapeutics (WINT) Stock Up 190% Today?
On an otherwise bearish day in the markets, many investors may be looking for some good news. For those on such a search, taking a look at some of the big movers in the biotech sector is a great place to start.
2022-11-18 13:41:20 - Zacks Investment Research
Windtree Therapeutics, Inc. (WINT) Upgraded to Buy: Here's Why
Windtree Therapeutics, Inc. (WINT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).